SLC7A11 and lung adenocarcinoma: These results indicate that KRAS mutant lung adenocarcinoma cells are vulnerable to SLC7A11 inhibition; however, as HG106 is not an approved drug from the United States Food and Drug Administration (FDA), efforts shifted toward SAS as it is FDA approved.